Incidence and prevalence of inflammatory bowel disease in Mexico from a nationwide cohort study in a period of 15 years (2000-2017).

Despite the worldwide increasing incidence and prevalence of Inflammatory Bowel Disease (IBD), our knowledge about it in Mexico is still limited. The aim of this study is to describe the incidence and prevalence of IBD as well as its clinical and socio-demographical characteristics in Mexico from a nation-wide perspective.Multicenter nation-wide cohort study that included 42 IBD clinics from all over the country that participated with electronically register of the new cases over 17 years as well as all known existing cases together with their clinical and socio-demographical characteristics from patients with IBD (ulcerative colitis [UC], Crohn disease [CD], and inflammatory bowel disease unclassified [IBDU]).

[Gastropathy caused by non-steroidal anti-inflammatory agents and its association with Helicobacter pylori].

Background: Upper gastrointestinal bleeding that is related with older patients and NSAIDs use. The frequency of peptic ulcer bleeding varies of 15% to 30% of cases.

Objective: To determine the gastropathy features of patients who receive nonsteroidal anti-inflammatory drug, and its relation with Helicobacter pylori (Hp).

[Survival in patients with liver cirrhosis at the Durango, IMSS Regional General Hospital].

Introduction: In Mexico, hepatic cirrhosis mortality exhibits important regional differences.

Aim: To analyze global survival of cirrhotic patients, according to etiology and functional status.

Material And Methods: Between March 1990 to August 1998, newly diagnosed patients with hepatic cirrhosis were included in a follow-up study.